Cooperative Agreement U27DD000545

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. The $445,708 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will fund a 3-year research project to: 1) define the impact of ABO(H) glycans on platelet binding to von Willebrand factor, and 2) identify ABO(H) antigen-carrying glycoproteins...

The U.S. National Heart Lung and Blood Institute awarded a Project Grant totaling $1,474,222.00 under the Cardiovascular Diseases Research program (CFDA 93.837) to The Medical College of Wisconsin, Inc. The grant funding supports research to investigate the relationship between low-density lipoprotein (LDL) cholesterol levels and hemostasis in patients with hemophilia A. Specifically, the research aims to explore how lower LDL cholesterol in hemophilia patients may lead to reduced von Willebrand...

The National Heart Lung and Blood Institute awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. This grant, awarded on January 15, 2025, supports research to investigate the mechanisms of thrombosis (blood clots) in patients with COVID-19 infection. The key objectives are to measure changes in the hemostatic (clotting) and fibrinolytic (clot-dissolving) systems in COVID-19 patients from initial...

This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...

This $500,000 Project Grant award from the U.S. Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program supports research to improve understanding of delayed diagnosis of venous thromboembolism (VTE) in ambulatory care settings. The project aims to leverage electronic health record (EHR) data and stakeholder expertise to identify risk factors, disparities, and outcomes associated with delayed and missed VTE diagnosis in...

This Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) aims to advance scientific understanding of von Willebrand factor and von Willebrand disease. The $2,363,224 award to The Washington University, effective May 15, 2025 through April 30, 2030, supports a program project consisting of 4 research projects and 3 supporting cores. The key products and services to be delivered under this grant include: Identifying common...

This $201,426 federal Project Grant awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports a 5-year training program in patient-oriented research in cardiovascular endocrinology at Brigham & Women's Hospital Inc. The program aims to address an impending manpower crisis in patient-oriented research by providing comprehensive, curriculum-based training and mentored research projects for motivated trainees committed...

This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...

The University of Louisville has been awarded a $600,000 Cooperative Agreement by the U.S. Department of Health and Human Services Administration for Community Living under the Empowering Older Adults and Adults with Disabilities through Chronic Disease Self-Management Education Programs - CFDA 93.734. The purpose of this 4-year award is to increase participation and sustainability of evidence-based chronic disease self-management education (CDSME) programs for older adults and individuals...

This federal Project Grant award of $306,871 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop an educational and actionable report-back system for individuals and healthcare providers (HCPs) to help reduce PFAS (per- and polyfluoroalkyl substances) exposure and improve cardiovascular health in rural communities. The award recipient, Million Marker Wellness Inc., will work with 20 individuals and 10 HCPs in rural Nevada to create...